Gemcitabine + cisplatin
Checked 2026-09-09
Advanced biliary tract cancer first line (with durvalumab or pembrolizumab); cisplatin-eligible urothelial cancer
Also called GemCis.
One cycle
every 21 days × 8 · about 24 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Cisplatin Cytotoxic chemotherapy (platinum) | 25 mg/m² (biliary) or 70 mg/m² day 1 (urothelial) | IV | D1, 8 | |
Gemcitabine Nucleoside analogue (deoxycytidine) | 1,000 mg/m² | IV | D1, 8 |
Cycles
8 (biliary, 24 weeks); 4-6 (urothelial)
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Notes
- TOPAZ-1 adds durvalumab 1,500 mg every 3 weeks for 8 cycles then every 4 weeks; KEYNOTE-966 adds pembrolizumab 200 mg every 3 weeks.
- In urothelial cancer cisplatin is 70 mg/m² on day 1 only (von der Maase, JCO 2000).
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Gemcitabine monotherapy
Frail patients or adjuvant when combinations are not tolerated
every 28 days × 6
Sacituzumab govitecan
Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies
every 21 days
Dose-dense MVAC
Muscle-invasive bladder cancer, cisplatin-eligible, before cystectomy
every 14 days × 3-4
Enfortumab vedotin + pembrolizumab
Locally advanced or metastatic urothelial cancer, first line, regardless of cisplatin eligibility
every 21 days
Intravesical BCG, induction and maintenance
High-risk non-muscle-invasive bladder cancer after complete TURBT
weekly × 6